A Phase I/II Study to Evaluate the Safety, Tolerability and Efficacy of PerioSept and Scaling and Root Planing in Subjects With Periodontitis
Latest Information Update: 14 Jan 2020
Price :
$35 *
At a glance
- Drugs Taurolidine (Primary)
- Indications Periodontitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Geistlich
- 16 Sep 2019 Status changed from active, no longer recruiting to completed.
- 18 Jan 2018 Planned End Date changed from 1 Feb 2018 to 1 Dec 2018.
- 18 Jan 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.